- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02716740
Study of Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery. (MUSCAADE)
Pilot Study of Branched Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.
Despite the demonstrable health and quality of life benefits, there are unknowns within consequences of obesity surgery. Weight loss composition is poorly understood. The objective is to have a significant loss of body fat and a limited loss of muscular weight.
A cohort study in the nutrition unit at Toulouse University Hospital shows that 3 months and 1 year after surgery, there are 2 phenotypes of patients. The first one is called 'little loss' and is defined by a contribution of muscular weight lower than 15% of the total weight loss. The other one is called 'big loss' and is defined by a contribution of muscular weight higher than 15% of the total weight loss. Causes of these different phenotypes are unknown for the moment.
Some amino acids have an anabolic potential. Leucine induces a muscular protein synthesis in clinical situations like hepatic cirrhosis, and some populations like new born and older people.
Assuming that, a leucine-enriched essential amino acid supplementation will have a benefit effect on the muscular mass. That is testing the influence of the quality of protein consumed, more than the quantity. An anabolic substance (amino acid here) can lead to gain of muscle only if it is associated to regular physical training, all patients will follow a physical training.
Study Overview
Status
Conditions
Detailed Description
An excessive loss of lean mass could have negative metabolic consequences. Indeed, lean mass is an essential determinant of weight loss and of the glycaemia regulation. An important loss of muscular mass could expose the person to a reduction of quality of life (because of fatigue), or even a functional loss. Muscles are important for insulin sensibility and glucose metabolism. Muscles are proteolysis target and proteins will be used as sources of amino acid for other cellular functions.
Changes in lean mass have been at the centre of several studies, but changes in muscular mass after bariatric surgery have been report only one time.
A cohort study in the nutrition unit at Toulouse University Hospital shows that 3 months and 1 year after surgery, there are 2 phenotypes of patients. The first one is called 'little loss' and is defined by a contribution of muscular weight lower than 15% of the total weight loss. The other one is called 'big loss' and is defined by a contribution of muscular weight higher than 15% of the total weight loss. Causes of these different phenotypes are unknown for the moment. Nothing distinguishes them before the surgery. Type of surgery, gender, protein intake (in grams of proteins intake per day) do not appear to have a determining influence about the intensity of muscle mass loss. The only other study published shows changes in muscular mass about 15% at 6 weeks.
Relation between glycaemia changes and muscle mass changes suggests that patients with modest changes in muscular mass are patients who have the best improvement of glycaemia after surgery. It is the reason why, it could be interesting to preserve muscular mass.
Nowadays, there is no consensual strategy to compensate this loss of muscle mass. It is important to have in the same time an anabolic stimulus (training, hormone…) and a sufficient energy and protein intake.
According to a recent study which compares leucine intake with placebo during weight loss driven by a low-calorie diet associated to a muscle strengthening exercises, patients loss the same weight, but leucin group is gaining lean mass, while placebo group is losing it. Accordingly, twe different doses of amino acid will be tested of those used as diet supplement.
This study is testing the influence of the quality of protein consumed, more than the quantity. Patients will take leucine-enriched amino acid supplement and follow physical training. Aromatic amino acid supplementation showed an anabolic effect in older people, undernourished children and undernourished patients with chronic obstructive pulmonary disease. There are no known side effects. This amino acid supplementation has not been evaluated in post-obesity surgery context.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- Department of Endocrinology, metabolic diseases and nutrition
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient older than 18 years of age and younger than 65 years of age,
- Patient received an obesity-surgery (gastric bypass or sleeve gastrectomy)
- Contribution of muscular weight higher than 15% of the total weight loss after the third month post-surgery.
- Patient that be able to increase their physical activity
- Patient that give their informed consent before any procedure for the study
- Patient affiliated with a health insurance scheme
Exclusion Criteria:
- Patients allergic to one of the supplement's compound.
- Patients with glucocorticoid therapy
- Patients with hyperthyroidism
- Patients commencing insulin treatment or growth hormone
- Protein powder intake (as nutritional complement or as anabolic substance for muscle building practice)
- Oral nutritional supplement intake for malnutrition
- Bone fracture since the surgery
- Infection can cause hypercatabolism (like microbial outbreak or chronic gastric fistula)
- Hospitalization for more than 24 hours since the surgery
- Known physical handicap
- Inability to increase physical activity during 3 months after beginning of the supplementation
- Enteral or parenteral nutrition
- Patients over 158 kg (DEXA impossible)
- Protected adults (guardianship by court order)
- Pregnant woman or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Leucine-enriched amino acid : 2.16g/day
Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
|
After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week).
Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
|
Experimental: Leucine-enriched amino acid : 4g/day
Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
|
After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week).
Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in appendicular muscular mass at 3 months
Time Frame: Baseline and 3 months
|
Appendicular muscular mass measured by dual-energy X-ray absorptiometry (DEXA).
It will be measured before and 3 months after supplementation.
|
Baseline and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in limbs muscular force at 3 months
Time Frame: Baseline and 3 months
|
The lower and higher limbs muscular force will be measured with a strain gauge.
|
Baseline and 3 months
|
Change from baseline in muscular function at 3 months
Time Frame: Baseline and 3 months
|
400 meters walking speed
|
Baseline and 3 months
|
Change from baseline in muscular function at 3 months
Time Frame: Baseline and 3 months
|
Chair-stand test
|
Baseline and 3 months
|
Change from baseline in muscular function at 3 months
Time Frame: Baseline and 3 months
|
Balance test by the Short Physical Performance Battery test
|
Baseline and 3 months
|
Change from baseline in fatigue at 3 months
Time Frame: Baseline and 3 months
|
Fatigue will be evaluate by the Pichot scale
|
Baseline and 3 months
|
Change from baseline in general functional assessment at 3 months
Time Frame: Baseline and 3 months
|
General function will be assessed by the Functional Status Questionnaire test.
|
Baseline and 3 months
|
Change from baseline in protein daily intake at 3 months
Time Frame: Baseline and 3 months
|
Patient will evaluate his/her protein daily intake (in g/day) by the Protein Intake Monitor with a digital tablet
|
Baseline and 3 months
|
Change from baseline in physical training adhesion at 3 months
Time Frame: Baseline and 3 months
|
Patients will have an exercise diary to write their organised physical activity.
Physical activity will be converted in a multiple of basal metabolic rate.
|
Baseline and 3 months
|
Change from baseline in glucose metabolism at 3 months
Time Frame: Baseline and 3 months
|
Oral glucose tolerance test will be performed and glucose concentration will be determined into the blood.
|
Baseline and 3 months
|
Change from baseline in insulin secretion at 3 months
Time Frame: Baseline and 3 months
|
Oral glucose tolerance test will be performed and insulin concentration will be determined into the blood.
|
Baseline and 3 months
|
Change from baseline in leucine compliance
Time Frame: Baseline and 3 months
|
Leucine concentration and variation between visit before and after 3 months of supplementation will be measured by chromatography to assess the patient's compliance
|
Baseline and 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: RITZ Patrick, MD PhD, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/15/7649
- 2015-A01226-43 (Other Identifier: RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week
-
Postgraduate Institute of Medical Education and...All India Institute of Medical Sciences, Bhubaneswar; Asian Institute of Gastroenterology... and other collaboratorsRecruitingAcute-On-Chronic Liver Failure | Hepatic EncephalopathyIndia
-
Poznan University of Physical EducationDavid C. Nieman; Tomasz Cisoń; Joanna Szurkowska; Mirosława Gałęcka; Dariusz Sitkowski and other collaboratorsCompleted
-
Umm Al-Qura UniversityCompletedDiabetic Peripheral NeuropathySaudi Arabia
-
Fundación Leucemia y Linfoma, SpainRoche Pharma AGCompletedNon-Hodgkin's LymphomaSpain
-
St. Jude Children's Research HospitalTerminated
-
National Cancer Institute (NCI)RecruitingStage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Guam, Puerto Rico
-
National Cancer Institute (NCI)RecruitingAdvanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditionsUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)Active, not recruitingB Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Acute Lymphoblastic Leukemia, BCR-ABL1-LikeUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland, Ireland
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent Hodgkin Lymphoma | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsUnited States